THC and CBD killed pediatric brain tumor cells in the lab but did not improve survival in mouse models | Research

The takeaway

THC and CBD reduced medulloblastoma and ependymoma cell viability in the lab, with synergistic effects when combined, but this did not translate to improved survival in animal brain tumor models.

Pediatric oncologists, cancer researchers, and families of children with brain tumors considering cannabinoid use.

In vitro cell killing did not translate to in vivo survival improvement

What the researchers found

THC and CBD induced dose-dependent cell death in medulloblastoma and ependymoma cell lines, with synergistic effects in combination. Mechanisms included cell cycle arrest, reactive oxygen species production, autophagy, and apoptosis. However, neither cannabinoids alone, in combination, nor combined with cyclophosphamide improved survival in orthotopic transplant models despite being well tolerated.

Why it matters

This study illustrates a critical gap in cancer cannabinoid research: laboratory cell-killing effects do not necessarily translate to meaningful tumor control in living organisms. It serves as a cautionary note against overinterpreting in vitro results.

The numbers in context

Dose-dependent cytotoxicity in vitro. Synergistic viability reduction when THC and CBD combined. No survival improvement in orthotopic models. No survival benefit from cannabinoid + cyclophosphamide combination. Treatment was well tolerated.

How the study worked

In vitro cytotoxicity, cell cycle, and mechanistic studies in medulloblastoma and ependymoma cell lines. In vivo orthotopic transplant models in mice for survival analysis. THC and CBD tested alone and in combination, and with the chemotherapy drug cyclophosphamide.

What this study cannot tell us

Orthotopic models may not perfectly replicate human pediatric brain tumors. Only one combination ratio and dosing schedule tested. The blood-brain barrier may have limited cannabinoid delivery to tumors. Cell line results may not represent tumor heterogeneity.

How to read the evidence

Comprehensive preclinical study with both in vitro and in vivo testing. The negative in vivo result is an important finding despite in vitro promise.

When this study was published

2021 study. Important negative result for cannabinoid use in pediatric brain cancers.

The bigger picture

The failure to translate in vitro effects to in vivo efficacy is a common problem in cancer drug development. This study emphasizes the importance of animal model testing before considering clinical trials, especially for vulnerable pediatric cancer patients.

Questions still open

Could different cannabinoid doses, routes, or schedules overcome the in vivo failure? Would cannabinoid-loaded nanoparticles improve brain tumor delivery? Are there other pediatric cancer types where cannabinoids might be more effective?

Common questions

Can cannabinoids treat pediatric brain tumors?

In this study, THC and CBD killed tumor cells in laboratory dishes but did not improve survival when tested in mouse brain tumor models. Clinical benefit for high-grade pediatric brain tumors is expected to be limited based on these results.

Why did lab results not translate to animal models?

The tumor microenvironment, blood-brain barrier, drug metabolism, and immune system all create conditions that differ from laboratory cell culture. Many compounds that kill cancer cells in dishes fail to work in living organisms.

Read the original research

Assessment of Cannabidiol and Δ9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma.

Cancers, 13(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Andradas, Clara; Byrne, Jacob; Kuchibhotla, Mani; Ancliffe, Mathew; Jones, Anya C; Carline, Brooke; Hii, Hilary; Truong, Alexandra; Storer, Lisa C D; Ritzmann, Timothy A; Grundy, Richard G; Gottardo, Nicholas G; Endersby, Raelene. (2021). Assessment of Cannabidiol and Δ9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma.. Cancers, 13(2). https://doi.org/10.3390/cancers13020330